Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 6/20 | 0.52 |
| ▸ | PLAU | P00749 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 8/20 | 0.50 |
| ▸ | F2 | P00734 | 7/20 | 0.50 |
| ▸ | F7 | P08709 | 3/20 | 0.50 |
| ▸ | PLG | P00747 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | PLAT | P00750 | 2/20 | 0.46 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.45 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973969 | 0.90 | CHEK2 (0.57) | CHEK2NPY5R | |
| SCHEMBL7969172 | 0.80 | NPC1 (0.53) | NPY5R | |
| SCHEMBL7962507 | 0.80 | NPY5R (0.60) | NPY5R | |
| SCHEMBL7973178 | 0.80 | NPY5R (0.56) | NPY5R | |
| SCHEMBL10140665 | 0.78 | MEN1 (0.45) | NPY5R | |
| SCHEMBL7973223 | 0.77 | NPY5R (0.62) | NPY5R | |
| SCHEMBL7962503 | 0.77 | NPY5R (0.52) | CHEK2NPY5R | |
| SCHEMBL7970001 | 0.77 | GFER (0.56) | NPY5R | |
| SCHEMBL3791087 | 0.73 | NPC1 (0.47) | NPY5R | |
| SCHEMBL3787151 | 0.70 | MEN1 (0.44) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | PRSS1 309/4885PLAU 67/4885F10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.